About Us

Drew Fromkin is the Chief Executive Officer of Pulmovant and has served as Vant Portfolio Operating Partner for Roivant Sciences, Inc. (ROIV) since January 2021. He currently serves on the Board of Immunovant (IMVT) as Chair of the Compensation and Nominating and Governance committees and previously served as the Chief Executive Officer of Proteovant Therapeutics.

Mr. Fromkin has an accomplished track record leading public and private companies at an operating and board level through all stages of development and value creation. Most notably, Mr. Fromkin served as President, Chief Executive Officer, and Director of Clinical Data, Inc. from 2006-2011. CLDA was sold to Forest Labs for a total consideration of $1.5 Billion. Mr. Fromkin has also served as Chairman and CEO of Tarveda Therapeutics, President and Chief Executive Officer of DoctorQuality, Inc. (sold to Quantros, Inc.), President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. (MRK). From 2014 until 2016, Mr. Fromkin also served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015  (sold to Allergan for $1.7 Billion). Mr. Fromkin earned his B.A. in biology from Brandeis University.  

Ubaldo has 30 years of experience in the practice of clinical and academic medicine and clinical drug development with an intensive focus in the respiratory and inhaled medicines fields. Once entering the pharmaceutical industry and prior to joining Pulmovant, Ubaldo served as the Vice President for Late Phase Development at AstraZeneca where he oversaw the development of a broad range of respiratory medications including biologics and inhaled small molecules. He also was an integral part of the teams at AstraZeneca that developed and ultimately launched benralizumab and tezepelumab. More recently he served as the Vice President and Head for Clinical Development at Pulmocide where he oversaw Phase 2 and Phase 3 clinical trials for a novel inhaled antifungal.

Ubaldo completed his residency in internal medicine and fellowship in pulmonary and critical care medicine at Temple University Hospital in Philadelphia, and he was part of the Temple University Pulmonary Division faculty where he also served as Head of the Pulmonary Function and Exercise Laboratory and Head of the Pulmonary Rehabilitation Program. He earned his MD from the University Francisco Marroquin in Guatemala.

Joe Bishop serves as Chief Financial Officer of Pulmovant and is Senior Vice President at Roivant Sciences, where he oversees strategic and financial operations of biopharmaceutical companies (Vants). Before joining Roivant in 2018, he was Head of Equities at Pine River Capital Management, a $15 billion multi-strategy investment firm where he led global investment decisions across a team of multi-sector equity portfolios.

Mr. Bishop earned his B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.

Jennifer Cormier serves as Senior Vice President, Clinical Operations for Pulmovant.  Jennifer has almost 20 years of pharmaceutical and medical device experience. She has led development stage drug programs from Phase 1 through Phase 4 post marketing approval studies across a range of therapeutic areas including rare genetic diseases, women’s health, Parkinson’s disease, diabetes/obesity, major depressive disorder, and hematologic oncology.  Prior to joining Pulmovant, Jennifer held senior clinical operations positions at Hemavant, PepGen, Relmada Therapeutics, and Sojournix.  Prior to Sojournix, she held various positions of increasing responsibilities in clinical operations, project management and Medical Affairs, leading global clinical programs and registry studies at Acorda Therapeutics, GI Dynamics and Shire. At Acorda, Jennifer led the Phase 3 Parkinson’s Disease Program for INBRIJA (levodopa inhalation powder), which was approved by the FDA and the EMA for the treatment of OFF episodes in Parkinson’s Disease.  She holds a B.S in Biology from University of Massachusetts Boston.

Carlos Sanmarco is the Senior Vice President - Program Leadership & Operations at Pulmovant, responsible for leading the mosliciguat program and overseeing the Program Management, CMC and business operations functions. Throughout his more than 20 years in drug development and clinical research at biotech and global pharma companies, Carlos has led research and development programs across a broad range of therapeutic areas, from candidate identification to launch. Prior to Pulmovant, Carlos was the Senior Vice President and Head of Program Management and Operations at Sonata Therapeutics (a Flagship Pioneering Company), and before that he served as the Vice President and Global Program Lead at Acceleron Pharma, responsible for overseeing the sotatercept program in pulmonary hypertension, from IND filing through Phase 3 completion, which led to the company acquisition by Merck & Co in 2021 for over $11 billion. At Acceleron Pharma, Carlos also coordinated and supervised the pulmonary therapeutic area strategy across all phases of development, including pre-clinical and early clinical development assets. Prior to Acceleron Pharma he served in various global leadership roles at Eli Lilly and Company, including Program Team Lead, Head of Clinical Operations and Medical Quality Lead. Carlos received his Pharm.D. and MBA from the University of Sao Paulo, Brazil.

Brian has more than 20 years of experience in the pharmaceutical industry with expertise in regulatory affairs and quality assurance across multiple therapeutic areas, including pulmonary, cardiovascular, and orphan diseases. He began his career at Wyeth Pharmaceuticals as a research scientist and transitioned into quality and regulatory affairs. He subsequently held roles of increasing responsibility at Shire, Actelion and Idorsia - most recently serving as Senior Vice President, Head of Global Drug Regulatory Affairs at Idorsia. Brian brings extensive experience from pre-IND through post-marketing stages for drugs evaluated to treat pulmonary diseases including pulmonary arterial hypertension and idopathic pulmonary fibrosis. He has provided integral contributions for the development of multiple approved endothelin receptor antagonists (bosentan, macitentan, aprocitentan) as well as the novel prostacyclin receptor agonist selexipag.

Brian received his B.A. in Chemistry from Swarthmore College, M.A. in Neurosciences from Washington University in St. Louis, and an M.S. in Regulatory Affairs and Quality Assurance from Temple University.

Amy Yoney is a seasoned professional with over two decades of experience in the field of rare diseases. Ms. Yoney began her career as a clinical research manager under the distinguished Dr Robyn J Barst at Columbia University, where her primary role was overseeing over 20 clinical trials in the realm of Pulmonary Arterial Hypertension (PAH).

In 2005 Ms Yoney took a role with Encysive Pharmaceuticals  assuming the role of Global Medical Science Liaison, and then later assuming the role of Country Lead for BENELUX.

With her collective experiences Ms Yoney established a consulting company of her own, collaborating with renowned organizations such as Bayer, Novartis, GeNO, AiRES and Lung Biotech, showcasing her commitment to driving innovation in rare disease therapy. 

Ms Yoney’s expertise extended to Reata Pharmaceuticals in 2015 serving as a Sr Director MSL overseeing Phase 2 trials in Pulmonary Arterial Hypertension/Connective Tissue Disease (PAH/CTD) and PAH/Interstitial Lung Disease (PAH/ILD).

Brian Farrer is the Executive Director, Pharmaceutical Development at Pulmovant.  Prior to joining Pulmovant, Brian was Senior Director of Preclinical Development at Inhalon Biopharma.  Brian has over 20 years of pharmaceutical development experience at Inhalon, Liquidia Technologies and Merck Research Laboratories.  At Liquidia, he managed pharmaceutical development of the inhaled portfolio, which included Yutrepia.  He received his PhD in chemistry from the University of North Carolina-Chapel Hill, and his BA in Chemistry and Mathematics from Northwestern University in Chicago.

Frank Torti is the Vant Chair at Roivant Sciences (NASDAQ: ROIV), Executive Chairman at Immunovant (NASDAQ: IMVT), and was the founding CEO & Chairman of Telavant from the time of its inception until its sale to Roche for $7.25B. 

In his role at Roivant, Dr. Torti serves as Chairman, Executive Chairman, or CEO of the public and private biopharmaceutical companies (Vants) at Roivant and is responsible for those businesses. This group of companies has advanced over forty medicines into clinical development, produced positive phase three results in ten consecutive clinical trials, and generated over fifteen billion dollars in value. Together these companies have delivered six FDA approvals and have brought novel medicines in dermatology, oncology, immunology, men’s and women’s health, and rare disease to millions of patients. 

Prior to joining Roivant, Dr. Torti was a partner at New Enterprise Associates (NEA), one of the largest venture capital firms in the world. Before joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of clinical trials. 

During the course of his career, Dr. Torti has been Chairman of the Board of fifteen companies and served on more than thirty corporate boards. He has been involved in more than $22 billion in capital formation through fundraising, partnerships, and corporate acquisitions, and companies with which he has been involved have completed approximately twenty initial public offerings and M&A transactions. 

Eric Venker, M.D., Pharm.D., is President and Chief Operating Officer of Roivant Sciences. He first joined Roivant in 2014 and has since served in various roles of increasing responsibility, most recently as COO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital and also worked in retail pharmacy settings. Dr. Venker presently serves on the boards of directors of Immunovant (NASDAQ: IMVT) and several other private company boards across biotechnology and health technology. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.  

Bill Gerhart has 25 years’ experience leading biopharma companies. Gerhart was most recently an entrepreneur-in-residence at Roivant helping to start and build companies as CEO or Board member. He was the founding CEO of Kinevant, a Roivant company formed to develop a novel mAb for the treatment of pulmonary sarcoidosis and potentially other inflammatory diseases. Prior to Kinevant, he was the CEO of Respivant, a Roivant company formed to develop a new inhaled therapy acquired from Patara Pharma for treating idiopathic pulmonary fibrosis. Prior to Roivant, he was the co-founder and CEO of Patara Pharma, the co-founder and CEO of Elevation Pharmaceuticals, developer of Lonhala® - an inhaled therapy for patients with severe COPD acquired and launched by Sunovion/Dainippon Sumitomo Pharma, and the co-founder and CEO of Mpex Pharmaceuticals, developer of Quinsair® - an inhaled antibiotic approved for the treatment of cystic fibrosis acquired and launched by Chiesi Pharmaceuticals. He has served on the Sanford Burnham Prebys Board of Trustees since 2013, an independent medical research institute - most recently as Chair. Gerhart has a BA from Baylor University and an MBA from Harvard Business School.